InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,009.55
(
-1.22%
)
US TECH 100
16,814.80
(
-1.44%
)
Dow Jones
37,847.43
(
-1.60%
)
Brent Oil
86.72
(
-0.58%
)
Bitcoin
63,781.50
(
-0.78%
)
Post# of 251594
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119477
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RockRat post# 214239

Tuesday, 11/21/2017 6:49:40 AM

Tuesday, November 21, 2017 6:49:40 AM

Post# of 251594
ARDX drops RDX7675 program—shares rise:

https://finance.yahoo.com/news/ardelyx-announces-updated-development-path-113000830.html

Ardelyx reported clinically meaningful potassium lowering activity from its onset-of-action study for RDX7675 for the treatment of hyperkalemia; however, the company also observed an unexpected side effect of decreased serum bicarbonate. The company believes this will limit the commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675.

CC today at 8:30am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up